Skip to main content
AstraZeneca Pharma India Ltd. logo

AstraZeneca Pharma India Ltd. — Investor Relations & Filings

Ticker · ASTRAZEN ISIN · INE203A01020 LEI · 335800N8M7W5JDTAHR68 BSE.NS Manufacturing
Open in API
Filings indexed 1,265 across all filing types
Latest filing 2020-11-13 Regulatory Filings
Country IN India
Listing BSE.NS ASTRAZEN

About AstraZeneca Pharma India Ltd.

https://www.astrazeneca.com/content/az-…

AstraZeneca Pharma India Ltd. is a science-led biopharmaceutical organization dedicated to the discovery, development, and commercialization of innovative prescription medicines. The company focuses on core therapeutic areas including Oncology, Cardiovascular, Renal & Metabolism, Respiratory & Immunology, and Rare Disease. Its product portfolio includes advanced treatments such as Tagrisso, Lynparza, and Imfinzi for various cancers, as well as Forxiga and Brilinta for metabolic and cardiovascular conditions. The company utilizes a robust global research pipeline to address complex medical challenges and improve patient outcomes. Through clinical research and specialized healthcare solutions, it delivers transformative therapies designed to treat chronic and life-threatening diseases. The organization is characterized by its commitment to scientific excellence and the delivery of high-value medical interventions.

Recent filings

Filing Released Lang Actions
Spurt in Volume
Regulatory Filings Classification · 100% confidence The document is a letter from AstraZeneca Pharma India Limited to the National Stock Exchange of India regarding an inquiry about an increase in trading volume. The company states it has no pending announcements that could affect the stock price or volume. The letter references compliance with SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, but contains no financial data, report, or detailed disclosure. It is a regulatory communication responding to a surveillance query rather than a financial report or announcement of a report. The document length is short (1126 characters), and it is not a report itself but a regulatory filing. Therefore, the appropriate classification is Regulatory Filings (RNS).
2020-11-13 English
Copy of Newspaper Publication
Regulatory Filings Classification · 90% confidence The document contains only placeholders for images and no textual content or substantive information. It is extremely short (218 characters) and does not contain any financial data, report titles, or regulatory references. Given the lack of content, it cannot be classified as a report or announcement. It fits best as a Regulatory Filing (RNS) as a fallback category for miscellaneous filings without clear classification.
2020-11-10 English
Pursuant to Regulation 47 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we are enclosing a copy of newspaper advertisement published in Business Standard ....
Regulatory Filings Classification · 90% confidence The document contains only placeholders for images and no textual content or substantive information. It is extremely short (218 characters) and does not contain any financial data, report content, or announcements. Given the lack of content, it cannot be classified as a report or detailed filing. It is best classified as a Regulatory Filing (RNS) as a fallback category for miscellaneous or incomplete filings.
2020-11-10 English
At the Board meeting of the Company held on Thursday, November 5, 2020 the Board of Directors considered and approved the Unaudited Financial Results of the Company for the quarter ended ....
Interim / Quarterly Report Classification · 100% confidence The document is dated November 5, 2020, and is from AstraZeneca Pharma India Limited. It contains unaudited financial results for the quarter and six months ended September 30, 2020, including a statement of assets and liabilities and a cash flow statement. The document also includes notes on accounting standards, COVID-19 impact, and other disclosures. There is a limited review report from the statutory auditors (Price Waterhouse & Co Chartered Accountants LLP) confirming the review of the interim financial information. The document references compliance with Indian Accounting Standard 34 (Interim Financial Reporting) and SEBI Listing Regulations for interim results. The presence of unaudited financial results for a quarter and half-year period, along with a limited review report, clearly identifies this as an Interim / Quarterly Report. The document length (over 14,000 characters) and detailed financial data confirm it is the report itself, not just an announcement or certification. Therefore, the appropriate classification is Interim / Quarterly Report (IR). H1 2021
2020-11-05 English
Financial Result Updates
Regulatory Filings
2020-11-05 English
Copy of Newspaper Publication
Regulatory Filings Classification · 90% confidence The document contains only references to omitted pictures and no textual content or substantive information. It is extremely short (218 characters) and does not contain any financial data, regulatory information, or report content. Given the lack of content, it cannot be classified as a report or detailed filing. It is best classified as a Regulatory Filing (RNS) as a fallback category for miscellaneous or insufficient filings.
2020-10-29 English

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.